NIH-funded study suggests opportunity to find insights to neurological disease.
A study in Neurology suggests that analyzing levels of the protein p75ECD in urine samples from people with amyotrophic lateral sclerosis (ALS) may help monitor disease progression as well as determine the effectiveness of therapies. The study was supported by National Institute of Neurological Disorders and Stroke (NINDS) and National Center for Advancing Translational Sciences (NCATS), both part of the National Institutes of Health.
“The study…suggests an objective new method for tracking the progression of this aggressive disease.”
—Amelie Gubitz, Ph.D., Program Director, NINDS
Mary-Louise Rogers, Ph.D., senior research fellow at Flinders University in Adelaide, Australia, and Michael Benatar, M.D., Ph.D, professor of neurology at the University of Miami, and their teams, discovered that levels of urinary p75 ECD increased gradually in patients with ALS as their disease progressed over a 2-year study period.
“It…
View original post 589 more words
Health Concierge. Telemedicine. Personalized Diet Plan 